Financial Report: Allergan

Allergan
 
1Q Revenue: $3.8 billion (+48%)

1Q Earnings: $256.4 million (loss of $512.3 million in 1Q15)

Comments: Global branded product revenues were $3.4 billion, up 70% driven by Botox, Restasis, and Fillers. Botox revenues in the quarter were $638 million, driven by continued strong performance in both aesthetic and therapeutic indications. Restasis revenues were $314 million, driven by strong promotional efforts. Fillers’ revenues were $215 million with continued strong performance. Namenda XR revenues in the first quarter of 2016 were $173 million, up 15%. Results were impacted by amortization, acquisition-related expenses, mainly the acquisition of Allergan on March 17, 2015. Results include Allergan results as of the date of the close of the acquisition, March 17, 2015. As a result of the proposed divestiture of Allergan’s Global Generics business to Teva on July 27, 2015, the financial results of the company’s Global Generics business are being reported as discontinued operations.